Follow
Fredrik Piehl
Fredrik Piehl
Professor of neurology, Karolinska Institutet
Verified email at ki.se
Title
Cited by
Cited by
Year
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
Nature 476 (7359), 214-219, 2011
30692011
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl, MP Sormani, T Gattringer, ...
Nature Reviews Neurology 14 (10), 577-589, 2018
17002018
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
International IBD Genetics Consortium (IIBDGC), C Agliardi, L Alfredsson, ...
Nature genetics 45 (11), 1353-1360, 2013
13732013
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility
International Multiple Sclerosis Genetics Consortium*†, ANZgene, ...
Science 365 (6460), eaav7188, 2019
10282019
Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium
TGM Van Erp, E Walton, DP Hibar, L Schmaal, W Jiang, DC Glahn, ...
Biological psychiatry 84 (9), 644-654, 2018
7912018
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind …
JF Howard, K Utsugisawa, M Benatar, H Murai, RJ Barohn, I Illa, S Jacob, ...
The Lancet Neurology 16 (12), 976-986, 2017
6572017
Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis
C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ...
JAMA neurology 76 (9), 1035-1048, 2019
6482019
Risk factors for amyotrophic lateral sclerosis
C Ingre, PM Roos, F Piehl, F Kamel, F Fang
Clinical epidemiology, 181-193, 2015
5702015
Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis
I Jelcic, F Al Nimer, J Wang, V Lentsch, R Planas, I Jelcic, A Madjovski, ...
Cell 175 (1), 85-100. e23, 2018
4722018
Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies
G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ...
JAMA neurology 77 (2), 184-191, 2020
4712020
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
L Novakova, H Zetterberg, P Sundström, M Axelsson, M Khademi, ...
Neurology 89 (22), 2230-2237, 2017
4392017
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction
M Swanberg, O Lidman, L Padyukov, P Eriksson, E Åkesson, M Jagodic, ...
Nature genetics 37 (5), 486-494, 2005
4142005
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
M Gunnarsson, C Malmeström, M Axelsson, P Sundström, C Dahle, ...
Annals of neurology 69 (1), 83-89, 2011
4132011
Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy
J Salzer, R Svenningsson, P Alping, L Novakova, A Björck, K Fink, ...
Neurology 87 (20), 2074-2081, 2016
3992016
Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study
J Kuhle, G Disanto, R Dobson, R Adiutori, L Bianchi, J Topping, ...
Multiple Sclerosis Journal 21 (8), 1013-1024, 2015
3902015
Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
H Hammarberg, O Lidman, C Lundberg, SY Eltayeb, AW Gielen, ...
Journal of Neuroscience 20 (14), 5283-5291, 2000
3732000
Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study
P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ...
The Lancet Neurology 21 (3), 246-257, 2022
3652022
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open …
R Kapoor, PR Ho, N Campbell, I Chang, A Deykin, F Forrestal, N Lucas, ...
The Lancet Neurology 17 (5), 405-415, 2018
3542018
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
3532020
T Cell Ig-and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived …
M Khademi, Z Illés, AW Gielen, M Marta, N Takazawa, C Baecher-Allan, ...
The Journal of Immunology 172 (11), 7169-7176, 2004
3232004
The system can't perform the operation now. Try again later.
Articles 1–20